NASDAQ:MGNX

MacroGenics Stock Forecast, Price & News

$25.63
+0.85 (+3.43 %)
(As of 08/5/2021 12:45 PM ET)
Add
Compare
Today's Range
$24.93
$25.77
50-Day Range
$20.49
$32.19
52-Week Range
$18.16
$36.48
Volume8,778 shs
Average Volume435,678 shs
Market Capitalization$1.57 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.25
30 days | 90 days | 365 days | Advanced Chart
Receive MGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.


MacroGenics logo

About MacroGenics

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.34 out of 5 stars

Medical Sector

210th out of 1,311 stocks

Pharmaceutical Preparations Industry

102nd out of 647 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











MacroGenics (NASDAQ:MGNX) Frequently Asked Questions

Is MacroGenics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last twelve months. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MacroGenics stock.
View analyst ratings for MacroGenics
or view top-rated stocks.

What stocks does MarketBeat like better than MacroGenics?

Wall Street analysts have given MacroGenics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MacroGenics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is MacroGenics' next earnings date?

MacroGenics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for MacroGenics
.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) posted its quarterly earnings data on Thursday, July, 29th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.38. The biopharmaceutical company earned $30.76 million during the quarter, compared to analysts' expectations of $35.55 million. MacroGenics had a negative net margin of 109.07% and a negative trailing twelve-month return on equity of 41.16%.
View MacroGenics' earnings history
.

How has MacroGenics' stock price been impacted by Coronavirus (COVID-19)?

MacroGenics' stock was trading at $6.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MGNX shares have increased by 284.7% and is now trading at $24.97.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MGNX?

6 brokers have issued 12 month price objectives for MacroGenics' shares. Their forecasts range from $17.00 to $41.00. On average, they expect MacroGenics' stock price to reach $34.40 in the next twelve months. This suggests a possible upside of 37.8% from the stock's current price.
View analysts' price targets for MacroGenics
or view top-rated stocks among Wall Street analysts.

Who are MacroGenics' key executives?

MacroGenics' management team includes the following people:
  • Scott E. Koenig, President, Chief Executive Officer & Director
  • James Karrels, Chief Financial Officer, Secretary & Senior VP
  • Ezio Bonvini, Chief Scientific Officer & Senior VP-Research
  • Stephen L. Eck, Chief Medical Officer & SVP-Clinical Development
  • Lynn Cilinski, Treasurer, Vice President & Controller

What is Scott Koenig's approval rating as MacroGenics' CEO?

12 employees have rated MacroGenics CEO Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among MacroGenics' employees.

Who are some of MacroGenics' key competitors?

What other stocks do shareholders of MacroGenics own?

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (2.75%), Pinnacle Associates Ltd. (0.70%), New York State Common Retirement Fund (0.12%), Russell Investments Group Ltd. (0.10%), Jackson Creek Investment Advisors LLC (0.07%) and Sanders Morris Harris LLC (0.03%). Company insiders that own MacroGenics stock include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Kenneth Galbraith, Target N V Biotech and Thomas Spitznagel.
View institutional ownership trends for MacroGenics
.

Which major investors are selling MacroGenics stock?

MGNX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Jackson Creek Investment Advisors LLC, Arizona State Retirement System, Sanders Morris Harris LLC, and New York State Common Retirement Fund. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Kenneth Galbraith, and Thomas Spitznagel.
View insider buying and selling activity for MacroGenics
or view top insider-selling stocks.

Which major investors are buying MacroGenics stock?

MGNX stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Pinnacle Associates Ltd., and Handelsbanken Fonder AB.
View insider buying and selling activity for MacroGenics
or or view top insider-buying stocks.

How do I buy shares of MacroGenics?

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $24.97.

How much money does MacroGenics make?

MacroGenics has a market capitalization of $1.53 billion and generates $104.88 million in revenue each year. The biopharmaceutical company earns $-129,740,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

How many employees does MacroGenics have?

MacroGenics employs 370 workers across the globe.

What is MacroGenics' official website?

The official website for MacroGenics is www.macrogenics.com.

Where are MacroGenics' headquarters?

MacroGenics is headquartered at 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at (301) 251-5172.


This page was last updated on 8/5/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.